Evidence review
How Long Does Semaglutide Take to Work? The Three Timelines That Get Confused
When semaglutide reaches full strength, when appetite changes, and when the scale moves — three different timelines, from the label and the trials.
Each semaglutide dose reaches full strength in about four to five weeks, because the drug's half-life is about a week3. You reach the 2.4 mg maintenance dose around week 173. Appetite may change within days or weeks, but in the STEP-1 trial, average weight loss kept climbing for the first eight to nine months1.
"How long until it works" sounds like one question. It is three, they run on different clocks, and confusing them is why so many people decide at week three that the medication failed.
Timeline one: the drug reaching full strength
Semaglutide has an elimination half-life of about one week3. A drug reaches steady state after roughly four to five half-lives, so a given dose is at its full, stable concentration around four to five weeks after you start it — not after the first injection.
That is per dose. You are also climbing a ladder. The label's escalation schedule steps the dose every four weeks, and the full maintenance dose of 2.4 mg once weekly is reached at week 17 by design3. So "how long until I am on the real dose" is a four-month answer, not a four-week one, and every step along the way spends its own month coming up to strength.
| What you are asking | Roughly how long | Why |
|---|---|---|
| Until this dose is at full strength | 4–5 weeks | ~1-week half-life, 4–5 half-lives to steady state |
| Until I reach the maintenance dose | ~16 weeks | the label steps the dose every 4 weeks |
| Until appetite changes | days to a few weeks | varies a lot between people |
| Until the scale moves meaningfully | months, not weeks | see the trial curves below |
Timeline two: appetite
This is the one people notice first, and it is the least predictable. Some people describe a clear drop in appetite within days of the first low dose; others feel almost nothing until the second or third step up. Both are normal, and neither predicts how well the drug will eventually work for you.
What is worth knowing: the starting dose is not a treatment dose. It exists to build tolerance to the gastrointestinal side effects, which is why the label starts everyone low and steps up rather than beginning at the effective dose3. If you feel nothing at 0.25 mg, that is the dose doing its actual job. Our dosing and titration guide sets out what the ladder should look like.
Timeline three: the scale — and this one is months
Here the trial data is unambiguous and much slower than the marketing. In STEP-1, the average weight-loss curve climbed steeply for roughly the first eight to nine months before flattening for the rest of the 68-week trial1. SURMOUNT-1 showed the same shape for tirzepatide across 72 weeks — a steep early phase, then a leveling off in the second half2.
Read that carefully, because it cuts both ways. Most of the weight in those trials came off over months, not weeks — so judging the medication at week four is judging it before it has finished arriving. And the flattening later is expected physiology, not failure; we cover that in the GLP-1 weight-loss plateau.
What "it isn't working" usually turns out to be
Four things, in rough order of frequency.
You are early. Week three on a starting dose is not a trial of the medication. It is the on-ramp.
You are not at a maintenance dose yet. 0.25 mg and 0.5 mg are escalation steps. If a provider left you at a starting dose for months, that is worth asking about directly.
The dose is right but the expectation was borrowed from someone else. Trial averages are averages; individual response varies widely, and a slower curve is not a failed one.
Something practical is off — a missed week, a storage problem that spoiled the pen, or a drawn dose that was not the intended dose. Two of those are avoidable: see how to store GLP-1 medication and, if you use compounded vials and a syringe, GLP-1 units to mg conversion, which is where the most common arithmetic error lives.
When to actually raise it with a prescriber
If you have reached a maintenance dose, held it for a couple of months, and the trend is genuinely flat — not one stalled week — that is a real conversation, and it might end in a dose change, a molecule change, or a look at what else is going on. If you are considering the second of those, semaglutide vs tirzepatide sets out how the two compare head to head.
The honest takeaway: the drug is at full strength for a given dose in about four to five weeks, you reach the maintenance dose around week 17, appetite may shift anywhere from days to weeks, and the weight curve in the trials took months. If you are three weeks in and disappointed, you are not looking at a failure — you are looking at the beginning.
References
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/35658024/
- U.S. Food and Drug Administration (2021). Wegovy (semaglutide) injection — Prescribing Information (label). FDA / Drugs@FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
Switching From Semaglutide to Tirzepatide: What Actually Happens
Whether you can switch GLP-1s, why your dose does not carry across, what the head-to-head trial found, and the questions worth asking before you move.
ReadTrumpRx GLP-1 Prices vs Telehealth: Wegovy, Ozempic, Zepbound in 2026
What TrumpRx charges for Wegovy, the Wegovy pill, Ozempic and Zepbound, which doses each price covers, and how they compare with telehealth plans.
ReadZepbound vs Wegovy: Weight Loss, Side Effects, Doses and 2026 Cash Price
Zepbound vs Wegovy compared on the head-to-head SURMOUNT-5 trial, dose schedules, side effects, Medicare coverage and what each costs without insurance in 2026.
ReadMedicare GLP-1 Bridge: Who Qualifies for $50-a-Month Wegovy, Zepbound or Foundayo
Who qualifies for Medicare GLP-1 Bridge, which drugs it covers for $50 a month, how to enroll, and what to do if you don't meet the BMI or plan rules.
ReadIs Retatrutide FDA Approved? Trial Results, Side Effects and When You Could Get It
Retatrutide is not FDA-approved. What the TRIUMPH trials showed, its side effects, when Lilly plans to file, and what you can take today instead.
ReadFoundayo (Orforglipron): Cost by Dose, Side Effects and Where to Get It
What Foundayo (orforglipron) costs at each dose, how the daily pill is taken, how much weight people lost in trials, side effects, and where to get it.
Read